Publications by authors named "Lyn A Smith"
Background And Aims: Carvedilol reduces rates of variceal bleeding and rebleeding by lowering portal pressure. However, an associated pleiotropic survival benefit has been proposed. We aimed to assess long-term survival in a cohort of patients previously randomised to receive either carvedilol or endoscopic band ligation (EBL) following oesophageal variceal bleeding (OVB).
View Article and Find Full Text PDFThe widespread use of cross-sectional imaging has led to an increased frequency of incidentally detected pancreatic cysts. Neoplastic cysts such as mucinous lesions and solid pseudo-papillary neoplasms have malignant potential and therefore the early detection of these lesions presents an opportunity for prevention or early detection and management of pancreatic adenocarcinoma. Serous neoplastic lesions and non-neoplastic pancreatic cysts such as pseudocysts or walled off pancreatic necrosis and are not associated with malignant potential.
View Article and Find Full Text PDFCatastrophic gastrointestinal complication of systemic immunosuppression.
World J Gastroenterol
February 2015
Article Synopsis
- A patient with systemic vasculitis, on immunosuppressive therapy, experienced acute upper gastrointestinal bleeding caused by severe oesophagitis and duodenitis.
- Biopsies indicated infections with herpes simplex virus (HSV) in the oesophagus and cytomegalovirus (CMV) in the duodenum, common issues in immunocompromised patients.
- The authors emphasize the importance of recognizing potential viral infections in these patients when they present with gastrointestinal bleeding, advocating for treatment with antiviral medications and possible adjustments to their immunosuppressive regimen.
Pancreatic cancer is the 10th most commonly diagnosed cancer in the UK and the fifth most common cause of cancer death. It remains one of the most aggressive cancers with over 95% of patients affected dying of their disease. Often presenting at an advanced stage of disease progression, there is currently no simple screening test available.
View Article and Find Full Text PDFBackground: Faecal calprotectin (FC) is a non-invasive marker of gastrointestinal inflammation.
Aim: To determine whether higher FC levels in individuals with quiescent Crohn's disease are associated with clinical relapse over the ensuing 12 months.
Methods: A single centre prospective study was undertaken in Crohn's disease patients in clinical remission.
Article Synopsis
- Hemospray TM (TC-325) is an innovative agent used in treating nonvariceal upper gastrointestinal bleeding (NVUGIB) in Europe, showing promising results in clinical settings.
- A study involving data from 10 European centers revealed that out of 63 patients treated, 87% achieved primary hemostasis, with a lower rebleeding rate of 15% in the following week.
- The findings suggest that TC-325 is effective both as a primary treatment and as a secondary option for patients who did not respond to initial therapies, demonstrating its versatility across various types of NVUGIB.
Utility of faecal calprotectin analysis in adult inflammatory bowel disease.
World J Gastroenterol
December 2012
The inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis, are chronic relapsing, remitting disorders. Diagnosis, along with assessment of disease activity and prognosis present challenges to managing clinicians. Faecal biomarkers, such as faecal calprotectin, are a non-invasive method which can be used to aid these decisions.
View Article and Find Full Text PDF